These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 11293937)

  • 1. [Levonorgestrel releasing intrauterine spiral--contraception and therapeutic indications].
    Kunz J
    Praxis (Bern 1994); 2001 Mar; 90(11):442-52. PubMed ID: 11293937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)--a systematic enquiry and overview.
    Varma R; Sinha D; Gupta JK
    Eur J Obstet Gynecol Reprod Biol; 2006 Mar; 125(1):9-28. PubMed ID: 16325993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term use of the levonorgestrel-releasing intrauterine system.
    Inki P
    Contraception; 2007 Jun; 75(6 Suppl):S161-6. PubMed ID: 17531611
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role of copper-releasing intrauterine device or levonorgestrel-releasing intrauterine system on uterine bleeding and iron status (prospective study of 8 years)].
    Imperato F; Perniola G; Mossa B; Marziani R; Perniola F; Stragapede B; Napolitano C
    Minerva Ginecol; 2002 Jun; 54(3):271-8. PubMed ID: 12063443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health effects of long-term use of the intrauterine levonorgestrel-releasing system. A follow-up study over 12 years of continuous use.
    Rönnerdag M; Odlind V
    Acta Obstet Gynecol Scand; 1999 Sep; 78(8):716-21. PubMed ID: 10468065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of oligoamenorrhea at 1-year follow-up in premenopausal women using a levonorgestrel-releasing intrauterine system.
    de Jonge ET; Yigit R; Molenberghs G; Straetmans D; Ombelet W
    Contraception; 2007 Aug; 76(2):91-5. PubMed ID: 17656176
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with the levonorgestrel-releasing intrauterine system among HIV-infected women.
    Lehtovirta P; Paavonen J; Heikinheimo O
    Contraception; 2007 Jan; 75(1):37-9. PubMed ID: 17161122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic use of the LNG IUS, and counseling.
    Pakarinen P; Toivonen J; Luukkainen T
    Semin Reprod Med; 2001 Dec; 19(4):365-72. PubMed ID: 11727178
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised comparative trial of the levonorgestrel intrauterine system and mefenamic acid for the treatment of idiopathic menorrhagia: a multiple analysis using total menstrual fluid loss, menstrual blood loss and pictorial blood loss assessment charts.
    Reid PC; Virtanen-Kari S
    BJOG; 2005 Aug; 112(8):1121-5. PubMed ID: 16045528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of menorrhagia with an LNG-IUS.
    Pakarinen P; Luukkainen T
    Contraception; 2007 Jun; 75(6 Suppl):S118-22. PubMed ID: 17531601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The levonorgestrel intrauterine system: more than a contraceptive.
    Andersson K
    Eur J Contracept Reprod Health Care; 2001 Jan; 6 Suppl 1():15-22. PubMed ID: 11336429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Menstrual blood loss in women using the frameless FibroPlant LNG-IUS.
    Andrade A; Wildemeersch D
    Contraception; 2009 Feb; 79(2):134-8. PubMed ID: 19135571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Femilis LNG-IUS: contraceptive performance-an interim analysis.
    Wildemeersch D; Janssens D; Andrade A
    Eur J Contracept Reprod Health Care; 2009 Apr; 14(2):103-10. PubMed ID: 19340705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progestin-releasing intrauterine systems and leiomyoma.
    Kaunitz AM
    Contraception; 2007 Jun; 75(6 Suppl):S130-3. PubMed ID: 17531604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The levonorgestrel intrauterine system: the benefits of reduced bleeding.
    Cameron IT
    Eur J Contracept Reprod Health Care; 2001 Jan; 6 Suppl 1():27-32. PubMed ID: 11336431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of levonorgestrel-releasing intrauterine system and T380A intrauterine copper device on dysmenorrhea and days of bleeding in women with and without adenomyosis.
    Kelekci S; Kelekci KH; Yilmaz B
    Contraception; 2012 Nov; 86(5):458-63. PubMed ID: 22832203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of menstrual blood loss in Belgian users of a new T-shaped levonorgestrel-releasing intrauterine system.
    Wildemeersch D; Rowe PJ
    Contraception; 2005 Jun; 71(6):470-3. PubMed ID: 15914139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Levonorgestrel-releasing intrauterine system: uses and controversies.
    Bahamondes L; Bahamondes MV; Monteiro I
    Expert Rev Med Devices; 2008 Jul; 5(4):437-45. PubMed ID: 18573044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The levonorgestrel-releasing intrauterine system as an alternative to hysterectomy in peri-menopausal women.
    Milsom I
    Contraception; 2007 Jun; 75(6 Suppl):S152-4. PubMed ID: 17531608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of the levonorgestrel-releasing intrauterine system Mirena versus the Copper T380A intrauterine device during lactation: breast-feeding performance, infant growth and infant development.
    Shaamash AH; Sayed GH; Hussien MM; Shaaban MM
    Contraception; 2005 Nov; 72(5):346-51. PubMed ID: 16246660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.